Category:
Carcinomas
Cancer type:
Bladder
Descriptor:
Met expression
Reference Number:
3
Cheng, H. L. et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation.
J Clin Oncol 20, 1544-50. (2002).
PubMed link
Reference Number:
400
[No authors listed] RON and MET co-expression is a prognostic indicator in bladder cancer patients.
Nat Clin Pract Urol. 2, 363 [Epub ahead of print] (2005)
PubMed link
Reference Number:
455
Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder.
Br J Cancer. 92, 1906-14 (2005)
PubMed link
Reference Number:
549
Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells.
Cell Cycle.
6, 1393-402 (2007)
PubMed link
Reference Number:
591
Wu TF, Wu H, Wang YW, Chang TY, Chan SH, Lin YP, Liu HS, Chow NH. Prohibitin in the pathogenesis of transitional cell bladder cancer.
Anticancer Res.
27, 895-900 (2007)
PubMed link
Reference Number:
592
Wang P, Nishitani MA, Tanimoto S, Kishimoto T, Fukumori T, Takahashi M, Kanayama HO. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor.
Urology.
69, 780-4 (2007)
PubMed link
Reference Number:
593
Todeschini AR, Dos Santos JN, Handa K, Hakomori SI. Ganglioside GM2-tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse.
J Biol Chem.
282, 8123-33 (2007)
PubMed link
Reference Number:
627
Compérat E, Roupret M, Chartier-Kastler E, Bitker MO, Richard F, Camparo P, Capron F, Cussenot O. Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract.
J Urol.
179, 868-72 (2008)
PubMed link
